Stock comparison
IDEXX Laboratories
TG Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
TGTX
TG Therapeutics
Market cap
$6.51B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TGTX | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 42D | IDXX |
| Benjamin Graham | 72B | 54C | IDXX |
| Philip Fisher | 67B | 50C | IDXX |
| Peter Lynch | 63C | 84A | TGTX |
| Joel Greenblatt | 75B | 55C | IDXX |
| Charlie Munger | 79B | 44D | IDXX |
| Terry Smith | 76B | 37D | IDXX |
Side-by-side metrics
| Metric | IDXX | TGTX |
|---|---|---|
| Market cap | $42.11B | $6.51B |
| P/E (TTM) | 39.0x | 13.3x |
| EV/EBIT | 31.6x | 55.3x |
| ROIC (TTM) | 40.66% | 11.13% |
| Gross margin | 62.05% | 83.04% |
| Net margin | 24.63% | 65.95% |
| Revenue CAGR 5y | 7.56% | 2.1% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$42.11Bvs $6.51B+85%
- ROIC (TTM)40.66%vs 11.13%+73%
- Debt / Equity0.7xvs 1.3x+46%
- EV/EBIT31.6xvs 55.3x+43%
TGTX leads on
- Revenue CAGR 5y2.1%vs 7.56%+96%
- P/E (TTM)13.3xvs 39.0x+66%
- Net margin65.95%vs 24.63%+63%
- Gross margin83.04%vs 62.05%+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.